Category: belantamab mafodotin

GSK’s Blenrep (belantamab mafodotin) Receives EC’s Approval for R/R Multiple Myeloma

approval, belantamab mafodotin, Blenrep, EC’s, GSK, r/r, receives, regulatory / August 27, 2020 August 27, 2020

Shots: The EC’s approval is based on DREAMM-2 study assessing Blenrep (2.5/ 3.4 mg/kg, q3w) as monothx. in adult patients prior treated with 4 therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 mAb, and who have demonstrated disease progression on the last therapy The data …

GSK’s Blenrep (belantamab mafodotin) Receives EC’s Approval for R/R Multiple Myeloma Read More »

GSK nabs FDA approval for first-in-class multiple myeloma drug

BCMA, belantamab mafodotin, BioPharma, biopharma nl, Blenrep, cancer, Daily, GlaxoSmithKline, London, multiple myeloma, Oncology, SYN, Top Story, U.K. / August 6, 2020 August 6, 2020

Blenrep, an antibody-drug conjugate, is the first drug approved for multiple myeloma that targets the antigen BCMA. Several other companies are also developing BCMA-targeting therapies for the blood cancer, including CAR-T cells and bispecific antibodies.

FDA AdCom votes unanimously in favor of GSK myeloma drug, despite earlier agency skepticism

AdCom, BCMA, belantamab mafodotin, BioPharma, biopharma nl, cancer, Daily, FDA, GlaxoSmithKline, London, multiple myeloma, ODAC, SYN, Top Story, U.K. / July 14, 2020 July 14, 2020

The Oncologic Drugs Advisory Committee voted 12-0 that the benefit-risk profile of belantamab mafodotin supported the drug. The vote came despite concerns expressed by the FDA in briefing documents ahead of the ODAC meeting, particularly with regard to ocular toxicity.

FDA raises concerns over ocular toxicity from GSK’s potential first-in-class myeloma drug

BCMA, belantamab mafodotin, BioPharma, biopharma nl, Daily, FDA, GlaxoSmithKline, London, multiple myeloma, Oncologic Drugs Advisory Committee, Policy, SYN, Top Story, U.K. / July 12, 2020 July 12, 2020

The FDA’s Oncologic Drugs Advisory Committee will convene Tuesday to discuss the drug, belantamab mafodotin. Despite the drug’s first-in-class potential, the briefing document for the meeting raised concerns about eye toxicity and questions about its risk-benefit profile.